[Skip to Content]
[Skip to Content Landing]
February 25, 2004

Magnesium Sulfate for Preterm Neuroprotection

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(8):940-941. doi:10.1001/jama.291.8.940-c

To the Editor: Dr Crowther and colleagues1 reported that the occurrence of a secondary, composite variable defined as "death or substantial motor dysfunction at a corrected age of 2 years" was significantly lower in the group exposed to magnesium sulfate. None of the individual outcomes, including cerebral palsy, was significantly different between the groups, although each was less common in the magnesium sulfate group.

First Page Preview View Large
First page PDF preview
First page PDF preview